



104TH GENERAL ASSEMBLY

State of Illinois

2025 and 2026

SB3221

Introduced 2/2/2026, by Sen. Julie A. Morrison

SYNOPSIS AS INTRODUCED:

720 ILCS 570/102	from Ch. 56 1/2, par. 1102
720 ILCS 570/204	from Ch. 56 1/2, par. 1204
720 ILCS 570/206	from Ch. 56 1/2, par. 1206
720 ILCS 570/208	from Ch. 56 1/2, par. 1208
720 ILCS 570/309.1 new	

Amends the Illinois Controlled Substances Act. Makes structural and other changes to the list of controlled substances. Adds xylazine as a Class III controlled substance. Provides that notwithstanding the scheduling of xylazine as a Schedule III controlled substance, xylazine shall not be considered a controlled substance when: (1) used by licensed Illinois veterinarians dispensing or prescribing for, or administering to, a nonhuman species of a drug containing xylazine that has been approved by the U.S. Food and Drug Administration; (2) used by licensed Illinois veterinarians dispensing or prescribing for, or administering to, a nonhuman species that is permissible under the Federal Food, Drug, and Cosmetic Act; (3) manufactured, distributed, or used as an active pharmaceutical ingredient for manufacturing an animal drug approved under the Federal Food, Drug, and Cosmetic Act; (4) used by a licensed certified euthanasia technician employed by a certified euthanasia agency; or (5) used by a wildlife biologist engaged in legal or authorized fieldwork under the indirect supervision of a veterinarian. Defines "isomer". Effective January 1, 2027.

LRB104 20204 RLC 33655 b

1 AN ACT concerning criminal law.

2 **Be it enacted by the People of the State of Illinois,**
3 **represented in the General Assembly:**

4 Section 5. The Illinois Controlled Substances Act is
5 amended by changing Sections 102, 204, 206, and 208 and by
6 adding Section 309.1 as follows:

7 (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102)

8 Sec. 102. Definitions. As used in this Act, unless the
9 context otherwise requires:

10 (a) "Person with a substance use disorder" means any
11 person who has a substance use disorder diagnosis defined as a
12 spectrum of persistent and recurring problematic behavior that
13 encompasses 10 separate classes of drugs: alcohol; caffeine;
14 cannabis; hallucinogens; inhalants; opioids; sedatives,
15 hypnotics and anxiolytics; stimulants; and tobacco; and other
16 unknown substances leading to clinically significant
17 impairment or distress.

18 (b) "Administer" means the direct application of a
19 controlled substance, whether by injection, inhalation,
20 ingestion, or any other means, to the body of a patient,
21 research subject, or animal (as defined by the Humane
22 Euthanasia in Animal Shelters Act) by:

23 (1) a practitioner (or, in his or her presence, by his

1 or her authorized agent),

2 (2) the patient or research subject pursuant to an
3 order, or

4 (3) a euthanasia technician as defined by the Humane
5 Euthanasia in Animal Shelters Act.

6 (c) "Agent" means an authorized person who acts on behalf
7 of or at the direction of a manufacturer, distributor,
8 dispenser, prescriber, or practitioner. It does not include a
9 common or contract carrier, public warehouseman or employee of
10 the carrier or warehouseman.

11 (c-1) "Anabolic Steroids" means any drug or hormonal
12 substance, chemically and pharmacologically related to
13 testosterone (other than estrogens, progestins,
14 corticosteroids, and dehydroepiandrosterone), and includes:

15 (i) 3[beta],17-dihydroxy-5a-androstane,

16 (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane,

17 (iii) 5[alpha]-androstan-3,17-dione,

18 (iv) 1-androstenediol (3[beta],

19 17[beta]-dihydroxy-5[alpha]-androst-1-ene),

20 (v) 1-androstenediol (3[alpha],

21 17[beta]-dihydroxy-5[alpha]-androst-1-ene),

22 (vi) 4-androstenediol

23 (3[beta],17[beta]-dihydroxy-androst-4-ene),

24 (vii) 5-androstenediol

25 (3[beta],17[beta]-dihydroxy-androst-5-ene),

26 (viii) 1-androstenedione

1 ([5alpha]-androst-1-en-3,17-dione),
2 (ix) 4-androstenedione
3 (androst-4-en-3,17-dione),
4 (x) 5-androstenedione
5 (androst-5-en-3,17-dione),
6 (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]-
7 hydroxyandrost-4-en-3-one),
8 (xii) boldenone (17[beta]-hydroxyandrost-
9 1,4,-diene-3-one),
10 (xiii) boldione (androsta-1,4-
11 diene-3,17-dione),
12 (xiv) calusterone (7[beta],17[alpha]-dimethyl-17
13 [beta]-hydroxyandrost-4-en-3-one),
14 (xv) clostebol (4-chloro-17[beta]-
15 hydroxyandrost-4-en-3-one),
16 (xvi) dehydrochloromethyltestosterone (4-chloro-
17 17[beta]-hydroxy-17[alpha]-methyl-
18 androst-1,4-dien-3-one),
19 (xvii) desoxymethyltestosterone
20 (17[alpha]-methyl-5[alpha]
21 -androst-2-en-17[beta]-ol) (a.k.a., madol),
22 (xviii) [delta]1-dihydrotestosterone (a.k.a.
23 '1-testosterone') (17[beta]-hydroxy-
24 5[alpha]-androst-1-en-3-one),
25 (xix) 4-dihydrotestosterone (17[beta]-hydroxy-
26 androstan-3-one),

- 1 (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl-
2 5[alpha]-androst-3-one),
3 (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-
4 hydroxyestr-4-ene),
5 (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-
6 1[beta],17[beta]-dihydroxyandrost-4-en-3-one),
7 (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],
8 17[beta]-dihydroxyandrost-1,4-dien-3-one),
9 (xxiv) furazabol (17[alpha]-methyl-17[beta]-
10 hydroxyandrostano[2,3-c]-furan),
11 (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one,
12 (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy-
13 androst-4-en-3-one),
14 (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]-
15 dihydroxy-estr-4-en-3-one),
16 (xxviii) mestanolone (17[alpha]-methyl-17[beta]-
17 hydroxy-5-androst-3-one),
18 (xxix) mesterolone (1-methyl-17[beta]-hydroxy-
19 [5a]-androst-3-one),
20 (xxx) methandienone (17[alpha]-methyl-17[beta]-
21 hydroxyandrost-1,4-dien-3-one),
22 (xxxii) methandriol (17[alpha]-methyl-3[beta],17[beta]-
23 dihydroxyandrost-5-ene),
24 (xxxiii) methenolone (1-methyl-17[beta]-hydroxy-
25 5[alpha]-androst-1-en-3-one),
26 (xxxiiii) 17[alpha]-methyl-3[beta], 17[beta]-

1 dihydroxy-5a-androstane,
2 (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy
3 -5a-androstane,
4 (xxxv) 17[alpha]-methyl-3[beta],17[beta]-
5 dihydroxyandrost-4-ene),
6 (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-
7 methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one),
8 (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-
9 hydroxyestra-4,9(10)-dien-3-one),
10 (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-
11 hydroxyestra-4,9-11-trien-3-one),
12 (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-
13 hydroxyandrost-4-en-3-one),
14 (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]-
15 hydroxyestr-4-en-3-one),
16 (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone
17 (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-
18 androst-1-en-3-one) (a.k.a. '17-[alpha]-methyl-
19 1-testosterone'),
20 (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one),
21 (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]-
22 dihydroxyestr-4-ene),
23 (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]-
24 dihydroxyestr-4-ene),
25 (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]-
26 dihydroxyestr-5-ene),

- 1 (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]-
2 dihydroxyestr-5-ene),
3 (xlvii) 19-nor-4,9(10)-androstadienedione
4 (estra-4,9(10)-diene-3,17-dione),
5 (xlviii) 19-nor-4-androstenedione (estr-4-
6 en-3,17-dione),
7 (xlix) 19-nor-5-androstenedione (estr-5-
8 en-3,17-dione),
9 (l) norbolethone (13[beta], 17a-diethyl-17[beta]-
10 hydroxygon-4-en-3-one),
11 (li) norclostebol (4-chloro-17[beta]-
12 hydroxyestr-4-en-3-one),
13 (lii) norethandrolone (17[alpha]-ethyl-17[beta]-
14 hydroxyestr-4-en-3-one),
15 (liii) normethandrolone (17[alpha]-methyl-17[beta]-
16 hydroxyestr-4-en-3-one),
17 (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-
18 2-oxa-5[alpha]-androstan-3-one),
19 (lv) oxymesterone (17[alpha]-methyl-4,17[beta]-
20 dihydroxyandrost-4-en-3-one),
21 (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-
22 17[beta]-hydroxy-(5[alpha]-androstan-3-one),
23 (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-
24 (5[alpha]-androst-2-eno[3,2-c]-pyrazole),
25 (lviii) stenbolone (17[beta]-hydroxy-2-methyl-
26 (5[alpha]-androst-1-en-3-one),

- 1 (lix) testolactone (13-hydroxy-3-oxo-13,17-
2 secoandrosta-1,4-dien-17-oic
3 acid lactone),
4 (lx) testosterone (17[beta]-hydroxyandrost-
5 4-en-3-one),
6 (lxi) tetrahydrogestrinone (13[beta], 17[alpha]-
7 diethyl-17[beta]-hydroxygon-
8 4,9,11-trien-3-one),
9 (lxii) trenbolone (17[beta]-hydroxyestr-4,9,
10 11-trien-3-one).

11 Any person who is otherwise lawfully in possession of an
12 anabolic steroid, or who otherwise lawfully manufactures,
13 distributes, dispenses, delivers, or possesses with intent to
14 deliver an anabolic steroid, which anabolic steroid is
15 expressly intended for and lawfully allowed to be administered
16 through implants to livestock or other nonhuman species, and
17 which is approved by the Secretary of Health and Human
18 Services for such administration, and which the person intends
19 to administer or have administered through such implants,
20 shall not be considered to be in unauthorized possession or to
21 unlawfully manufacture, distribute, dispense, deliver, or
22 possess with intent to deliver such anabolic steroid for
23 purposes of this Act.

24 (d) "Administration" means the Drug Enforcement
25 Administration, United States Department of Justice, or its
26 successor agency.

1 (d-5) "Clinical Director, Prescription Monitoring Program"
2 means a Department of Human Services administrative employee
3 licensed to either prescribe or dispense controlled substances
4 who shall run the clinical aspects of the Department of Human
5 Services Prescription Monitoring Program and its Prescription
6 Information Library.

7 (d-10) "Compounding" means the preparation and mixing of
8 components, excluding flavorings, (1) as the result of a
9 prescriber's prescription drug order or initiative based on
10 the prescriber-patient-pharmacist relationship in the course
11 of professional practice or (2) for the purpose of, or
12 incident to, research, teaching, or chemical analysis and not
13 for sale or dispensing. "Compounding" includes the preparation
14 of drugs or devices in anticipation of receiving prescription
15 drug orders based on routine, regularly observed dispensing
16 patterns. Commercially available products may be compounded
17 for dispensing to individual patients only if both of the
18 following conditions are met: (i) the commercial product is
19 not reasonably available from normal distribution channels in
20 a timely manner to meet the patient's needs and (ii) the
21 prescribing practitioner has requested that the drug be
22 compounded.

23 (e) "Control" means to add a drug or other substance, or
24 immediate precursor, to a Schedule whether by transfer from
25 another Schedule or otherwise.

26 (f) "Controlled Substance" means (i) a drug, substance,

1 immediate precursor, or synthetic drug in the Schedules of
2 Article II of this Act or (ii) a drug or other substance, or
3 immediate precursor, designated as a controlled substance by
4 the Department through administrative rule. The term does not
5 include distilled spirits, wine, malt beverages, or tobacco,
6 as those terms are defined or used in the Liquor Control Act of
7 1934 and the Tobacco Products Tax Act of 1995.

8 (f-5) "Controlled substance analog" means a substance:

9 (1) the chemical structure of which is substantially
10 similar to the chemical structure of a controlled
11 substance in Schedule I or II;

12 (2) which has a stimulant, depressant, or
13 hallucinogenic effect on the central nervous system that
14 is substantially similar to or greater than the stimulant,
15 depressant, or hallucinogenic effect on the central
16 nervous system of a controlled substance in Schedule I or
17 II; or

18 (3) with respect to a particular person, which such
19 person represents or intends to have a stimulant,
20 depressant, or hallucinogenic effect on the central
21 nervous system that is substantially similar to or greater
22 than the stimulant, depressant, or hallucinogenic effect
23 on the central nervous system of a controlled substance in
24 Schedule I or II.

25 (g) "Counterfeit substance" means a controlled substance,
26 which, or the container or labeling of which, without

1 authorization bears the trademark, trade name, or other
2 identifying mark, imprint, number or device, or any likeness
3 thereof, of a manufacturer, distributor, or dispenser other
4 than the person who in fact manufactured, distributed, or
5 dispensed the substance.

6 (h) "Deliver" or "delivery" means the actual, constructive
7 or attempted transfer of possession of a controlled substance,
8 with or without consideration, whether or not there is an
9 agency relationship. "Deliver" or "delivery" does not include
10 the donation of drugs to the extent permitted under the
11 Illinois Drug Reuse Opportunity Program Act.

12 (i) "Department" means the Illinois Department of Human
13 Services (as successor to the Department of Alcoholism and
14 Substance Abuse) or its successor agency.

15 (j) (Blank).

16 (k) "Department of Corrections" means the Department of
17 Corrections of the State of Illinois or its successor agency.

18 (l) "Department of Financial and Professional Regulation"
19 means the Department of Financial and Professional Regulation
20 of the State of Illinois or its successor agency.

21 (m) "Depressant" means any drug that (i) causes an overall
22 depression of central nervous system functions, (ii) causes
23 impaired consciousness and awareness, and (iii) can be
24 habit-forming or lead to a substance misuse or substance use
25 disorder, including, but not limited to, alcohol, cannabis and
26 its active principles and their analogs, benzodiazepines and

1 their analogs, barbiturates and their analogs, opioids
2 (natural and synthetic) and their analogs, and chloral hydrate
3 and similar sedative hypnotics.

4 (n) (Blank).

5 (o) "Director" means the Director of the Illinois State
6 Police or his or her designated agents.

7 (p) "Dispense" means to deliver a controlled substance to
8 an ultimate user or research subject by or pursuant to the
9 lawful order of a prescriber, including the prescribing,
10 administering, packaging, labeling, or compounding necessary
11 to prepare the substance for that delivery.

12 (q) "Dispenser" means a practitioner who dispenses.

13 (r) "Distribute" means to deliver, other than by
14 administering or dispensing, a controlled substance.

15 (s) "Distributor" means a person who distributes.

16 (t) "Drug" means (1) substances recognized as drugs in the
17 official United States Pharmacopoeia, Official Homeopathic
18 Pharmacopoeia of the United States, or official National
19 Formulary, or any supplement to any of them; (2) substances
20 intended for use in diagnosis, cure, mitigation, treatment, or
21 prevention of disease in man or animals; (3) substances (other
22 than food) intended to affect the structure of any function of
23 the body of man or animals and (4) substances intended for use
24 as a component of any article specified in clause (1), (2), or
25 (3) of this subsection. It does not include devices or their
26 components, parts, or accessories.

1 (t-3) "Electronic health record" or "EHR" means an
2 electronic record of health-related information on an
3 individual that is created, gathered, managed, and consulted
4 by authorized health care clinicians and staff.

5 (t-3.5) "Electronic health record system" or "EHR system"
6 means any computer-based system or combination of federally
7 certified Health IT Modules (defined at 42 CFR 170.102 or its
8 successor) used as a repository for electronic health records
9 and accessed or updated by a prescriber or authorized
10 surrogate in the ordinary course of his or her medical
11 practice. For purposes of connecting to the Prescription
12 Information Library maintained by the Bureau of Pharmacy and
13 Clinical Support Systems or its successor, an EHR system may
14 connect to the Prescription Information Library directly or
15 through all or part of a computer program or system that is a
16 federally certified Health IT Module maintained by a third
17 party and used by the EHR system to secure access to the
18 database.

19 (t-4) "Emergency medical services personnel" has the
20 meaning ascribed to it in the Emergency Medical Services (EMS)
21 Systems Act.

22 (t-5) "Euthanasia agency" means an entity certified by the
23 Department of Financial and Professional Regulation for the
24 purpose of animal euthanasia that holds an animal control
25 facility license or animal shelter license under the Animal
26 Welfare Act. A euthanasia agency is authorized to purchase,

1 store, possess, and utilize Schedule II nonnarcotic and
2 Schedule III nonnarcotic drugs for the sole purpose of animal
3 euthanasia.

4 (t-10) "Euthanasia drugs" means Schedule II or Schedule
5 III substances (nonnarcotic controlled substances) that are
6 used by a euthanasia agency for the purpose of animal
7 euthanasia.

8 (u) "Good faith" means the prescribing or dispensing of a
9 controlled substance by a practitioner in the regular course
10 of professional treatment to or for any person who is under his
11 or her treatment for a pathology or condition other than that
12 individual's physical or psychological dependence upon a
13 controlled substance, except as provided herein: and
14 application of the term to a pharmacist shall mean the
15 dispensing of a controlled substance pursuant to the
16 prescriber's order which in the professional judgment of the
17 pharmacist is lawful. The pharmacist shall be guided by
18 accepted professional standards, including, but not limited
19 to, the following, in making the judgment:

20 (1) lack of consistency of prescriber-patient
21 relationship,

22 (2) frequency of prescriptions for same drug by one
23 prescriber for large numbers of patients,

24 (3) quantities beyond those normally prescribed,

25 (4) unusual dosages (recognizing that there may be
26 clinical circumstances where more or less than the usual

1 dose may be used legitimately),

2 (5) unusual geographic distances between patient,
3 pharmacist and prescriber,

4 (6) consistent prescribing of habit-forming drugs.

5 (u-0.5) "Hallucinogen" means a drug that causes markedly
6 altered sensory perception leading to hallucinations of any
7 type.

8 (u-1) "Home infusion services" means services provided by
9 a pharmacy in compounding solutions for direct administration
10 to a patient in a private residence, long-term care facility,
11 or hospice setting by means of parenteral, intravenous,
12 intramuscular, subcutaneous, or intraspinal infusion.

13 (u-5) "Illinois State Police" means the Illinois State
14 Police or its successor agency.

15 (v) "Immediate precursor" means a substance:

16 (1) which the Department has found to be and by rule
17 designated as being a principal compound used, or produced
18 primarily for use, in the manufacture of a controlled
19 substance;

20 (2) which is an immediate chemical intermediary used
21 or likely to be used in the manufacture of such controlled
22 substance; and

23 (3) the control of which is necessary to prevent,
24 curtail or limit the manufacture of such controlled
25 substance.

26 (w) "Instructional activities" means the acts of teaching,

1 educating or instructing by practitioners using controlled
2 substances within educational facilities approved by the State
3 Board of Education or its successor agency.

4 (w-1) "Isomer" means optical isomer, unless specifically
5 detailed in this Act.

6 (x) "Local authorities" means a duly organized State,
7 County or Municipal peace unit or police force.

8 (y) "Look-alike substance" means a substance, other than a
9 controlled substance which (1) by overall dosage unit
10 appearance, including shape, color, size, markings or lack
11 thereof, taste, consistency, or any other identifying physical
12 characteristic of the substance, would lead a reasonable
13 person to believe that the substance is a controlled
14 substance, or (2) is expressly or impliedly represented to be
15 a controlled substance or is distributed under circumstances
16 which would lead a reasonable person to believe that the
17 substance is a controlled substance. For the purpose of
18 determining whether the representations made or the
19 circumstances of the distribution would lead a reasonable
20 person to believe the substance to be a controlled substance
21 under this clause (2) of subsection (y), the court or other
22 authority may consider the following factors in addition to
23 any other factor that may be relevant:

24 (a) statements made by the owner or person in control
25 of the substance concerning its nature, use or effect;

26 (b) statements made to the buyer or recipient that the

1 substance may be resold for profit;

2 (c) whether the substance is packaged in a manner
3 normally used for the illegal distribution of controlled
4 substances;

5 (d) whether the distribution or attempted distribution
6 included an exchange of or demand for money or other
7 property as consideration, and whether the amount of the
8 consideration was substantially greater than the
9 reasonable retail market value of the substance.

10 Clause (1) of this subsection (y) shall not apply to a
11 noncontrolled substance in its finished dosage form that was
12 initially introduced into commerce prior to the initial
13 introduction into commerce of a controlled substance in its
14 finished dosage form which it may substantially resemble.

15 Nothing in this subsection (y) prohibits the dispensing or
16 distributing of noncontrolled substances by persons authorized
17 to dispense and distribute controlled substances under this
18 Act, provided that such action would be deemed to be carried
19 out in good faith under subsection (u) if the substances
20 involved were controlled substances.

21 Nothing in this subsection (y) or in this Act prohibits
22 the manufacture, preparation, propagation, compounding,
23 processing, packaging, advertising or distribution of a drug
24 or drugs by any person registered pursuant to Section 510 of
25 the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).

26 (y-1) "Mail-order pharmacy" means a pharmacy that is

1 located in a state of the United States that delivers,
2 dispenses or distributes, through the United States Postal
3 Service or other common carrier, to Illinois residents, any
4 substance which requires a prescription.

5 (z) "Manufacture" means the production, preparation,
6 propagation, compounding, conversion or processing of a
7 controlled substance other than methamphetamine, either
8 directly or indirectly, by extraction from substances of
9 natural origin, or independently by means of chemical
10 synthesis, or by a combination of extraction and chemical
11 synthesis, and includes any packaging or repackaging of the
12 substance or labeling of its container, except that this term
13 does not include:

14 (1) by an ultimate user, the preparation or
15 compounding of a controlled substance for his or her own
16 use;

17 (2) by a practitioner, or his or her authorized agent
18 under his or her supervision, the preparation,
19 compounding, packaging, or labeling of a controlled
20 substance:

21 (a) as an incident to his or her administering or
22 dispensing of a controlled substance in the course of
23 his or her professional practice; or

24 (b) as an incident to lawful research, teaching or
25 chemical analysis and not for sale; or

26 (3) the packaging, repackaging, or labeling of drugs

1 only to the extent permitted under the Illinois Drug Reuse
2 Opportunity Program Act.

3 (z-1) (Blank).

4 (z-5) "Medication shopping" means the conduct prohibited
5 under subsection (a) of Section 314.5 of this Act.

6 (z-10) "Mid-level practitioner" means (i) a physician
7 assistant who has been delegated authority to prescribe
8 through a written delegation of authority by a physician
9 licensed to practice medicine in all of its branches, in
10 accordance with Section 7.5 of the Physician Assistant
11 Practice Act of 1987, (ii) an advanced practice registered
12 nurse who has been delegated authority to prescribe through a
13 written delegation of authority by a physician licensed to
14 practice medicine in all of its branches or by a podiatric
15 physician, in accordance with Section 65-40 of the Nurse
16 Practice Act, (iii) an advanced practice registered nurse
17 certified as a nurse practitioner, nurse midwife, or clinical
18 nurse specialist who has been granted authority to prescribe
19 by a hospital affiliate in accordance with Section 65-45 of
20 the Nurse Practice Act, (iv) an animal euthanasia agency, or
21 (v) a prescribing psychologist.

22 (aa) "Narcotic drug" means any of the following, whether
23 produced directly or indirectly by extraction from substances
24 of vegetable origin, or independently by means of chemical
25 synthesis, or by a combination of extraction and chemical
26 synthesis:

1 (1) opium, opiates, derivatives of opium and opiates,
2 including their isomers, esters, ethers, salts, and salts
3 of isomers, esters, and ethers, whenever the existence of
4 such isomers, esters, ethers, and salts is possible within
5 the specific chemical designation; however the term
6 "narcotic drug" does not include the isoquinoline
7 alkaloids of opium;

8 (2) (blank);

9 (3) opium poppy and poppy straw;

10 (4) coca leaves, except coca leaves and extracts of
11 coca leaves from which substantially all of the cocaine
12 and ecgonine, and their isomers, derivatives and salts,
13 have been removed;

14 (5) cocaine, its salts, optical and geometric isomers,
15 and salts of isomers;

16 (6) ecgonine, its derivatives, their salts, isomers,
17 and salts of isomers;

18 (7) any compound, mixture, or preparation which
19 contains any quantity of any of the substances referred to
20 in subparagraphs (1) through (6).

21 (bb) "Nurse" means a registered nurse licensed under the
22 Nurse Practice Act.

23 (cc) (Blank).

24 (dd) "Opiate" means a drug derived from or related to
25 opium.

26 (ee) "Opium poppy" means the plant of the species *Papaver*

1 somniferum L., except its seeds.

2 (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
3 solution or other liquid form of medication intended for
4 administration by mouth, but the term does not include a form
5 of medication intended for buccal, sublingual, or transmucosal
6 administration.

7 (ff) "Parole and Pardon Board" means the Parole and Pardon
8 Board of the State of Illinois or its successor agency.

9 (gg) "Person" means any individual, corporation,
10 mail-order pharmacy, government or governmental subdivision or
11 agency, business trust, estate, trust, partnership or
12 association, or any other entity.

13 (hh) "Pharmacist" means any person who holds a license or
14 certificate of registration as a registered pharmacist, a
15 local registered pharmacist or a registered assistant
16 pharmacist under the Pharmacy Practice Act.

17 (ii) "Pharmacy" means any store, ship or other place in
18 which pharmacy is authorized to be practiced under the
19 Pharmacy Practice Act.

20 (ii-5) "Pharmacy shopping" means the conduct prohibited
21 under subsection (b) of Section 314.5 of this Act.

22 (ii-10) "Physician" (except when the context otherwise
23 requires) means a person licensed to practice medicine in all
24 of its branches.

25 (jj) "Poppy straw" means all parts, except the seeds, of
26 the opium poppy, after mowing.

1 (kk) "Practitioner" means a physician licensed to practice
2 medicine in all its branches, dentist, optometrist, podiatric
3 physician, veterinarian, scientific investigator, pharmacist,
4 physician assistant, advanced practice registered nurse,
5 licensed practical nurse, registered nurse, emergency medical
6 services personnel, hospital, laboratory, or pharmacy, or
7 other person licensed, registered, or otherwise lawfully
8 permitted by the United States or this State to distribute,
9 dispense, conduct research with respect to, administer or use
10 in teaching or chemical analysis, a controlled substance in
11 the course of professional practice or research.

12 (ll) "Pre-printed prescription" means a written
13 prescription upon which the designated drug has been indicated
14 prior to the time of issuance; the term does not mean a written
15 prescription that is individually generated by machine or
16 computer in the prescriber's office.

17 (mm) "Prescriber" means a physician licensed to practice
18 medicine in all its branches, dentist, optometrist,
19 prescribing psychologist licensed under Section 4.2 of the
20 Clinical Psychologist Licensing Act with prescriptive
21 authority delegated under Section 4.3 of the Clinical
22 Psychologist Licensing Act, podiatric physician, or
23 veterinarian who issues a prescription, a physician assistant
24 who issues a prescription for a controlled substance in
25 accordance with Section 303.05, a written delegation, and a
26 written collaborative agreement required under Section 7.5 of

1 the Physician Assistant Practice Act of 1987, an advanced
2 practice registered nurse with prescriptive authority
3 delegated under Section 65-40 of the Nurse Practice Act and in
4 accordance with Section 303.05, a written delegation, and a
5 written collaborative agreement under Section 65-35 of the
6 Nurse Practice Act, an advanced practice registered nurse
7 certified as a nurse practitioner, nurse midwife, or clinical
8 nurse specialist who has been granted authority to prescribe
9 by a hospital affiliate in accordance with Section 65-45 of
10 the Nurse Practice Act and in accordance with Section 303.05,
11 or an advanced practice registered nurse certified as a nurse
12 practitioner, nurse midwife, or clinical nurse specialist who
13 has full practice authority pursuant to Section 65-43 of the
14 Nurse Practice Act.

15 (nn) "Prescription" means a written, facsimile, or oral
16 order, or an electronic order that complies with applicable
17 federal requirements, of a physician licensed to practice
18 medicine in all its branches, dentist, podiatric physician or
19 veterinarian for any controlled substance, of an optometrist
20 in accordance with Section 15.1 of the Illinois Optometric
21 Practice Act of 1987, of a prescribing psychologist licensed
22 under Section 4.2 of the Clinical Psychologist Licensing Act
23 with prescriptive authority delegated under Section 4.3 of the
24 Clinical Psychologist Licensing Act, of a physician assistant
25 for a controlled substance in accordance with Section 303.05,
26 a written delegation, and a written collaborative agreement

1 required under Section 7.5 of the Physician Assistant Practice
2 Act of 1987, of an advanced practice registered nurse with
3 prescriptive authority delegated under Section 65-40 of the
4 Nurse Practice Act who issues a prescription for a controlled
5 substance in accordance with Section 303.05, a written
6 delegation, and a written collaborative agreement under
7 Section 65-35 of the Nurse Practice Act, of an advanced
8 practice registered nurse certified as a nurse practitioner,
9 nurse midwife, or clinical nurse specialist who has been
10 granted authority to prescribe by a hospital affiliate in
11 accordance with Section 65-45 of the Nurse Practice Act and in
12 accordance with Section 303.05 when required by law, or of an
13 advanced practice registered nurse certified as a nurse
14 practitioner, nurse midwife, or clinical nurse specialist who
15 has full practice authority pursuant to Section 65-43 of the
16 Nurse Practice Act.

17 (nn-5) "Prescription Information Library" (PIL) means an
18 electronic library that contains reported controlled substance
19 data.

20 (nn-10) "Prescription Monitoring Program" (PMP) means the
21 entity that collects, tracks, and stores reported data on
22 controlled substances and select drugs pursuant to Section
23 316.

24 (oo) "Production" or "produce" means manufacture,
25 planting, cultivating, growing, or harvesting of a controlled
26 substance other than methamphetamine.

1 (pp) "Registrant" means every person who is required to
2 register under Section 302 of this Act.

3 (qq) "Registry number" means the number assigned to each
4 person authorized to handle controlled substances under the
5 laws of the United States and of this State.

6 (qq-5) "Secretary" means, as the context requires, either
7 the Secretary of the Department or the Secretary of the
8 Department of Financial and Professional Regulation, and the
9 Secretary's designated agents.

10 (rr) "State" includes the State of Illinois and any state,
11 district, commonwealth, territory, insular possession thereof,
12 and any area subject to the legal authority of the United
13 States of America.

14 (rr-5) "Stimulant" means any drug that (i) causes an
15 overall excitation of central nervous system functions, (ii)
16 causes impaired consciousness and awareness, and (iii) can be
17 habit-forming or lead to a substance use disorder, including,
18 but not limited to, amphetamines and their analogs,
19 methylphenidate and its analogs, cocaine, and phencyclidine
20 and its analogs.

21 (rr-10) "Synthetic drug" includes, but is not limited to,
22 any synthetic cannabinoids or piperazines or any synthetic
23 cathinones as provided for in Schedule I.

24 (ss) "Ultimate user" means a person who lawfully possesses
25 a controlled substance for his or her own use or for the use of
26 a member of his or her household or for administering to an

1 animal owned by him or her or by a member of his or her
2 household.

3 (Source: P.A. 102-389, eff. 1-1-22; 102-538, eff. 8-20-21;
4 102-813, eff. 5-13-22; 103-881, eff. 1-1-25.)

5 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)

6 Sec. 204. (a) The controlled substances listed in this
7 Section are included in Schedule I.

8 (b) Unless specifically excepted or unless listed in
9 another schedule, any of the following opiates, including
10 their isomers, esters, ethers, salts, and salts of isomers,
11 esters, and ethers, whenever the existence of such isomers,
12 esters, ethers and salts is possible within the specific
13 chemical designation:

14 (1) Acetylmethadol;

15 (1.1) (Blank); ~~Acetyl-alpha-methylfentanyl~~

16 ~~(N-[1-(1-methyl-2-phenethyl)-~~

17 ~~4-piperidinyl] N-phenylacetamide);~~

18 (2) Allylprodine;

19 (3) Alphacetylmethadol, except
20 levo-alphacetylmethadol (also known as levo-alpha-
21 acetylmethadol, levomethadyl acetate, or LAAM);

22 (4) Alphameprodine;

23 (5) Alphamethadol;

24 (6) Alpha-methylfentanyl

25 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)

- 1 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
- 2 propanilido) piperidine;
- 3 (6.1) (Blank); ~~Alpha-methylthiofentanyl~~
- 4 ~~(N-[1-methyl-2-(2-thienyl)ethyl-~~
- 5 ~~4-piperidinyl]-N-phenylpropanamide);~~
- 6 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
- 7 (7.1) PEPAP
- 8 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 9 (8) Benzethidine;
- 10 (9) Betacetylmethadol;
- 11 (9.1) (Blank); ~~Beta-hydroxyfentanyl~~
- 12 ~~(N-[1-(2-hydroxy-2-phenethyl)-~~
- 13 ~~4-piperidinyl]-N-phenylpropanamide);~~
- 14 (10) Betameprodine;
- 15 (11) Betamethadol;
- 16 (12) Betaprodine;
- 17 (12.1) Brorphine;
- 18 (13) Clonitazene;
- 19 (14) Dextromoramide;
- 20 (15) Diampromide;
- 21 (16) Diethylthiambutene;
- 22 (17) Difenoquin;
- 23 (18) Dimenoxadol;
- 24 (19) Dimepheptanol;
- 25 (20) Dimethylthiambutene;
- 26 (21) Dioxaphetylbutyrate;

- 1 (22) Dipipanone;
- 2 (23) Ethylmethylthiambutene;
- 3 (24) Etonitazene;
- 4 (25) Etoxeridine;
- 5 (25.1) Flunitazene;
- 6 (26) Furethidine;
- 7 (27) Hydroxypethidine;
- 8 (27.1) Isotonitazene;
- 9 (28) Ketobemidone;
- 10 (29) Levomoramide;
- 11 (30) Levophenacymorphan;
- 12 (31) (Blank); ~~3-Methylfentanyl~~
- 13 ~~(N-[3-methyl-1-(2-phenylethyl)-~~
- 14 ~~4-piperidyl]-N-phenylpropanamide);~~
- 15 (31.1) (Blank); ~~3-Methylthiofentanyl~~
- 16 ~~(N-[(3-methyl-1-(2-thienyl)ethyl-~~
- 17 ~~4-piperidinyl]-N-phenylpropanamide);~~
- 18 (31.2) Metonitazene;
- 19 (32) Morpheridine;
- 20 (33) Noracymethadol;
- 21 (34) Norlevorphanol;
- 22 (35) Normethadone;
- 23 (36) Norpipanone;
- 24 (36.1) (Blank); ~~Para-fluorofentanyl~~
- 25 ~~(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-~~
- 26 ~~4-piperidinyl]propanamide);~~

- 1 (37) Phenadoxone;
- 2 (38) Phenampromide;
- 3 (39) Phenomorphan;
- 4 (40) Phenoperidine;
- 5 (41) Piritramide;
- 6 (42) Proheptazine;
- 7 (43) Properidine;
- 8 (44) Propiram;
- 9 (45) Racemoramide;
- 10 (45.1) (Blank); ~~Thiofentanyl~~
- 11 ~~(N-phenyl-N-[1-(2-thienyl)ethyl-~~
- 12 ~~4-piperidinyl]-propanamide);~~
- 13 (46) Tilidine;
- 14 (47) Trimeperidine;
- 15 (48) (Blank); ~~Beta-hydroxy-3-methylfentanyl (other~~
- 16 ~~name:~~
- 17 ~~N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-~~
- 18 ~~N-phenylpropanamide);~~
- 19 (49) (Blank); ~~Furanyl fentanyl (FU-F);~~
- 20 (50) (Blank); ~~Butyryl fentanyl;~~
- 21 (51) (Blank); ~~Valeryl fentanyl;~~
- 22 (52) (Blank); ~~Acetyl fentanyl;~~
- 23 (53) (Blank); ~~Beta-hydroxy-thiofentanyl;~~
- 24 (54) 3,4-dichloro-N-[2-
- 25 (dimethylamino)cyclohexyl]-N-
- 26 methylbenzamide (U-47700);

1 (55) 4-chloro-N-[1-[2-
2 (4-nitrophenyl)ethyl]-2-piperidinylidene]-
3 benzenesulfonamide (W-18);

4 (56) 4-chloro-N-[1-(2-phenylethyl)
5 -2-piperidinylidene]-benzenesulfonamide (W-15);

6 (57) (Blank). ~~acrylfentanyl (acryloylfentanyl)~~.

7 (c) Unless specifically excepted or unless listed in
8 another schedule, any of the following opium derivatives, its
9 salts, isomers and salts of isomers, whenever the existence of
10 such salts, isomers and salts of isomers is possible within
11 the specific chemical designation:

- 12 (1) Acetorphine;
- 13 (2) Acetyldihydrocodeine;
- 14 (3) Benzylmorphine;
- 15 (4) Codeine methylbromide;
- 16 (5) Codeine-N-Oxide;
- 17 (6) Cyprenorphine;
- 18 (7) Desomorphine;
- 19 (8) Diacetyldihydromorphine (Dihydroheroin);
- 20 (9) Dihydromorphine;
- 21 (10) Drotebanol;
- 22 (11) Etorphine (except hydrochloride salt);
- 23 (12) Heroin;
- 24 (13) Hydromorphanol;
- 25 (14) Methyldesorphine;
- 26 (15) Methyldihydromorphine;

- 1 (16) Morphine methylbromide;
- 2 (17) Morphine methylsulfonate;
- 3 (18) Morphine-N-Oxide;
- 4 (19) Myrophine;
- 5 (20) Nicocodeine;
- 6 (21) Nicomorphine;
- 7 (22) Normorphine;
- 8 (23) Pholcodine;
- 9 (24) Thebacon.

10 (d) Unless specifically excepted or unless listed in
11 another schedule, any material, compound, mixture, or
12 preparation which contains any quantity of the following
13 hallucinogenic substances, or which contains any of its salts,
14 isomers and salts of isomers, whenever the existence of such
15 salts, isomers, and salts of isomers is possible within the
16 specific chemical designation (for the purposes of this
17 paragraph only, the term "isomer" includes the optical,
18 position and geometric isomers):

- 19 (1) 3,4-methylenedioxyamphetamine
20 (alpha-methyl,3,4-methylenedioxyphenethylamine,
21 methylenedioxyamphetamine, MDA);
22 (1.1) Alpha-ethyltryptamine
23 (some trade or other names: etryptamine;
24 MONASE; alpha-ethyl-1H-indole-3-ethanamine;
25 3-(2-aminobutyl)indole; a-ET; and AET);
26 (2) 3,4-methylenedioxymethamphetamine (MDMA);

- 1 (2.1) 3,4-methylenedioxy-N-ethylamphetamine
2 (also known as: N-ethyl-alpha-methyl-
3 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
4 and MDEA);
- 5 (2.2) (Blank); ~~N-Benzylpiperazine (BZP);~~
6 (2.2-1) (Blank); ~~Trifluoromethylphenylpiperazine~~
7 ~~(TFMPP);~~
- 8 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
9 (4) 3,4,5-trimethoxyamphetamine (TMA);
10 (5) (Blank);
11 (6) Diethyltryptamine (DET);
12 (7) Dimethyltryptamine (DMT);
13 (7.1) 5-Methoxy-diallyltryptamine;
14 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
15 (9) Ibogaine (some trade and other names:
16 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
17 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
18 indole; Tabernanthe iboga);
- 19 (10) Lysergic acid diethylamide;
20 (10.1) Salvinorin A;
21 (10.5) Salvia divinorum (meaning all parts of the
22 plant presently classified botanically as Salvia
23 divinorum, whether growing or not, the seeds thereof, any
24 extract from any part of that plant, and every compound,
25 manufacture, salts, isomers, and salts of isomers whenever
26 the existence of such salts, isomers, and salts of isomers

1 is possible within the specific chemical designation,
2 derivative, mixture, or preparation of that plant, its
3 seeds or extracts);

4 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);

5 (12) Peyote (meaning all parts of the plant presently
6 classified botanically as *Lophophora williamsii* Lemaire,
7 whether growing or not, the seeds thereof, any extract
8 from any part of that plant, and every compound,
9 manufacture, salts, derivative, mixture, or preparation of
10 that plant, its seeds or extracts);

11 (13) N-ethyl-3-piperidyl benzilate (JB 318);

12 (14) N-methyl-3-piperidyl benzilate;

13 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
14 (also known as N-hydroxy-alpha-methyl-
15 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);

16 (15) Parahexyl; some trade or other names:
17 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
18 dibenzo (b,d) pyran; Synhexyl;

19 (16) Psilocybin;

20 (17) Psilocyn;

21 (18) Alpha-methyltryptamine (AMT);

22 (19) 2,5-dimethoxyamphetamine
23 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);

24 (20) 4-bromo-2,5-dimethoxyamphetamine
25 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
26 4-bromo-2,5-DMA);

1 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.

2 Some trade or other names: 2-(4-bromo-

3 2,5-dimethoxyphenyl)-1-aminoethane;

4 alpha-desmethyl DOB, 2CB, Nexus;

5 (21) 4-methoxyamphetamine

6 (4-methoxy-alpha-methylphenethylamine;

7 paramethoxyamphetamine; PMA);

8 (22) (Blank);

9 (23) Ethylamine analog of phencyclidine.

10 Some trade or other names:

11 N-ethyl-1-phenylcyclohexylamine,

12 (1-phenylcyclohexyl) ethylamine,

13 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;

14 (24) Pyrrolidine analog of phencyclidine. Some trade

15 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,

16 PHP;

17 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;

18 (26) 2,5-dimethoxy-4-ethylamphetamine

19 (another name: DOET);

20 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine

21 (another name: TCPy);

22 (28) (Blank);

23 (29) Thiophene analog of phencyclidine (some trade

24 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;

25 2-thienyl analog of phencyclidine; TPCP; TCP);

26 (29.1) Benzothiophene analog of phencyclidine. Some

1 trade or other names: BTCP or benocyclidine;
2 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
3 (30) Bufotenine (some trade or other names:
4 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
5 3-(2-dimethylaminoethyl)-5-indolol;
6 5-hydroxy-N,N-dimethyltryptamine;
7 N,N-dimethylserotonin; mappine);
8 (31) (Blank);
9 (32) (Blank);
10 (33) (Blank);
11 (34) (Blank);
12 (34.5) (Blank);
13 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
14 (2-methyloctan-2-yl)-6a,7,
15 10,10a-tetrahydrobenzo[c]chromen-1-ol
16 Some trade or other names: HU-210;
17 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-
18 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
19 tetrahydrobenzo[c]chromen-1-ol, its isomers,
20 salts, and salts of isomers; Some trade or other
21 names: HU-210, Dexanabinol;
22 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
23 6,6-dimethyl-3-(2-methyloctan-2-yl)-
24 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
25 Some trade or other names: HU-211;
26 (37) (Blank);

1 (38) (Blank);

2 (39) (Blank);

3 (40) (Blank);

4 (41) (Blank);

5 (42) (Blank); ~~Any compound structurally derived from~~

6 ~~3-(1-naphthoyl)indole or~~

7 ~~1H-indol-3-yl-(1-naphthyl)methane by substitution at the~~

8 ~~nitrogen atom of the indole ring by alkyl, haloalkyl,~~

9 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,~~

10 ~~alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or~~

11 ~~2-(4-morpholinyl)ethyl whether or not further substituted~~

12 ~~in the indole ring to any extent, whether or not~~

13 ~~substituted in the naphthyl ring to any extent. Examples~~

14 ~~of this structural class include, but are not limited to,~~

15 ~~JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;~~

16 (43) (Blank); ~~Any compound structurally derived from~~

17 ~~3-(1-naphthoyl)pyrrole by substitution at the nitrogen~~

18 ~~atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,~~

19 ~~cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl~~

20 ~~halide, 1-(N-methyl-2-piperidinyl)methyl, or~~

21 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~

22 ~~in the pyrrole ring to any extent, whether or not~~

23 ~~substituted in the naphthyl ring to any extent. Examples~~

24 ~~of this structural class include, but are not limited to,~~

25 ~~JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;~~

26 (44) (Blank); ~~Any compound structurally derived from~~

1 ~~1-(1-naphthylmethyl)indene by substitution at the~~
2 ~~3 position of the indene ring by alkyl, haloalkyl,~~
3 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,~~
4 ~~alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
5 ~~2-(4-morpholinyl)ethyl whether or not further substituted~~
6 ~~in the indene ring to any extent, whether or not~~
7 ~~substituted in the naphthyl ring to any extent. Examples~~
8 ~~of this structural class include, but are not limited to,~~
9 ~~JWH 176;~~

10 (45) (Blank); ~~Any compound structurally derived from~~
11 ~~3-phenylacetylindole by substitution at the nitrogen atom~~
12 ~~of the indole ring with alkyl, haloalkyl, alkenyl,~~
13 ~~cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl~~
14 ~~halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
15 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
16 ~~in the indole ring to any extent, whether or not~~
17 ~~substituted in the phenyl ring to any extent. Examples of~~
18 ~~this structural class include, but are not limited to,~~
19 ~~JWH 167, JWH 250, JWH 251, and RCS 8;~~

20 (46) (Blank); ~~Any compound structurally derived from~~
21 ~~2-(3-hydroxycyclohexyl)phenol by substitution at the~~
22 ~~5 position of the phenolic ring by alkyl, haloalkyl,~~
23 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,~~
24 ~~alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
25 ~~2-(4-morpholinyl)ethyl, whether or not substituted in the~~
26 ~~cyclohexyl ring to any extent. Examples of this structural~~

1 ~~class include, but are not limited to, CP 47, 497 and its~~
2 ~~C8 homologue (cannabicyclohexanol);~~

3 (46.1) (Blank); ~~Any compound structurally derived from~~
4 ~~3-(benzoyl) indole with substitution at the nitrogen atom~~
5 ~~of the indole ring by an alkyl, haloalkyl, alkenyl,~~
6 ~~cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl~~
7 ~~halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
8 ~~2-(4-morpholinyl)ethyl group whether or not further~~
9 ~~substituted in the indole ring to any extent and whether~~
10 ~~or not substituted in the phenyl ring to any extent.~~
11 ~~Examples of this structural class include, but are not~~
12 ~~limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN~~
13 ~~48,098), and RCS-4;~~

14 (47) (Blank);

15 (48) (Blank);

16 (49) (Blank);

17 (50) (Blank);

18 (51) (Blank);

19 (52) (Blank);

20 (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.

21 Some trade or other names: 2C-T-7;

22 (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some
23 trade or other names: 2C-E;

24 (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
25 trade or other names: 2C-D;

26 (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some

1 trade or other names: 2C-C;

2 (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
3 or other names: 2C-I;

4 (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
5 trade or other names: 2C-T-2;

6 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
7 Some trade or other names: 2C-T-4;

8 (53.7) 2,5-dimethoxyphenethylamine. Some trade or
9 other names: 2C-H;

10 (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some
11 trade or other names: 2C-N;

12 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
13 trade or other names: 2C-P;

14 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.
15 Some trade or other names: 2C-G;

16 (53.11) The N-(2-methoxybenzyl) derivative of any 2C
17 phenethylamine referred to in subparagraphs (20.1), (53),
18 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
19 (53.8), (53.9), and (53.10) including, but not limited to,
20 25I-NBOMe and 25C-NBOMe;

21 (54) 5-Methoxy-N,N-diisopropyltryptamine;

22 (55) (Blank);

23 (56) (Blank);

24 (57) (Blank);

25 (58) (Blank);

26 (59) (Blank); ~~3-cyclopropoylindole with substitution~~

1 ~~at the nitrogen atom of the indole ring by alkyl,~~
2 ~~haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,~~
3 ~~aryl halide, alkyl aryl halide,~~
4 ~~1-(N-methyl-2-piperidinyl)methyl, or~~
5 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
6 ~~on the indole ring to any extent, whether or not~~
7 ~~substituted on the cyclopropyl ring to any extent:~~
8 ~~including, but not limited to, XLR11, UR144, FUB 144;~~

9 (60) (Blank); ~~3-adamantoylindole with substitution at~~
10 ~~the nitrogen atom of the indole ring by alkyl, haloalkyl,~~
11 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,~~
12 ~~alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
13 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
14 ~~on the indole ring to any extent, whether or not~~
15 ~~substituted on the adamantyl ring to any extent:~~
16 ~~including, but not limited to, AB 001;~~

17 (61) (Blank); ~~N-(adamantyl) indole 3-carboxamide with~~
18 ~~substitution at the nitrogen atom of the indole ring by~~
19 ~~alkyl, haloalkyl, alkenyl, cycloalkylmethyl,~~
20 ~~cycloalkylethyl, aryl halide, alkyl aryl halide,~~
21 ~~1-(N-methyl-2-piperidinyl)methyl, or~~
22 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
23 ~~on the indole ring to any extent, whether or not~~
24 ~~substituted on the adamantyl ring to any extent:~~
25 ~~including, but not limited to, APICA/2NE-1, STS 135;~~

26 (62) (Blank); ~~N-(adamantyl) indazole 3-carboxamide~~

1 ~~with substitution at a nitrogen atom of the indazole ring~~
2 ~~by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,~~
3 ~~cycloalkylethyl, aryl halide, alkyl aryl halide,~~
4 ~~1-(N-methyl-2-piperidinyl)methyl, or~~
5 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
6 ~~on the indazole ring to any extent, whether or not~~
7 ~~substituted on the adamantyl ring to any extent:~~
8 ~~including, but not limited to, AKB48, 5F AKB48;~~

9 (63) (Blank); ~~1H-indole-3-carboxylic acid~~
10 ~~8-quinolinyl ester with substitution at the nitrogen atom~~
11 ~~of the indole ring by alkyl, haloalkyl, alkenyl,~~
12 ~~cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl~~
13 ~~halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
14 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
15 ~~on the indole ring to any extent, whether or not~~
16 ~~substituted on the quinoline ring to any extent:~~
17 ~~including, but not limited to, PB22, 5F PB22, FUB PB 22;~~

18 (64) (Blank); ~~3-(1-naphthoyl)indazole with~~
19 ~~substitution at the nitrogen atom of the indazole ring by~~
20 ~~alkyl, haloalkyl, alkenyl, cycloalkylmethyl,~~
21 ~~cycloalkylethyl, aryl halide, alkyl aryl halide,~~
22 ~~1-(N-methyl-2-piperidinyl)methyl, or~~
23 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
24 ~~on the indazole ring to any extent, whether or not~~
25 ~~substituted on the naphthyl ring to any extent: including,~~
26 ~~but not limited to, THJ 018, THJ 2201;~~

1 (65) ~~(Blank); 2-(1-naphthoyl)benzimidazole with~~
2 ~~substitution at the nitrogen atom of the benzimidazole~~
3 ~~ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,~~
4 ~~cycloalkylethyl, aryl halide, alkyl aryl halide,~~
5 ~~1-(N-methyl-2-piperidinyl)methyl, or~~
6 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
7 ~~on the benzimidazole ring to any extent, whether or not~~
8 ~~substituted on the naphthyl ring to any extent: including,~~
9 ~~but not limited to, FUBIMINA;~~

10 (66) ~~(Blank); N-(1-amino-3-methyl-1-oxobutan-2-yl)-~~
11 ~~1H-indazole-3-carboxamide with substitution on the~~
12 ~~nitrogen atom of the indazole ring by alkyl, haloalkyl,~~
13 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,~~
14 ~~alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
15 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
16 ~~on the indazole ring to any extent: including, but not~~
17 ~~limited to, AB-PINACA, AB-FUBINACA, AB-CHIMINACA;~~

18 (67) ~~(Blank); N-(1-amino-3,3-dimethyl-1-oxobutan-~~
19 ~~2-yl)-1H-indazole-3-carboxamide with substitution on the~~
20 ~~nitrogen atom of the indazole ring by alkyl, haloalkyl,~~
21 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,~~
22 ~~alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
23 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
24 ~~on the indazole ring to any extent: including, but not~~
25 ~~limited to, ADB-PINACA, ADB-FUBINACA;~~

26 (68) ~~(Blank); N-(1-amino-3,3-dimethyl-1-oxobutan-~~

1 ~~2-yl) 1H-indole 3-carboxamide with substitution on the~~
2 ~~nitrogen atom of the indole ring by alkyl, haloalkyl,~~
3 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,~~
4 ~~alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
5 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
6 ~~on the indole ring to any extent: including, but not~~
7 ~~limited to, ABBICA, 5F-ABBICA;~~

8 (69) (Blank); ~~N-(1-amino-3-methyl-1-oxobutan-2-~~
9 ~~yl) 1H-indole 3-carboxamide with substitution on the~~
10 ~~nitrogen atom of the indole ring by alkyl, haloalkyl,~~
11 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,~~
12 ~~alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
13 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
14 ~~on the indole ring to any extent: including, but not~~
15 ~~limited to, ABICA, 5F-ABICA;~~

16 (70) (Blank); ~~Methyl 2-(1H-indazole 3-carboxamido)-3-~~
17 ~~methylbutanoate with substitution on the nitrogen atom of~~
18 ~~the indazole ring by alkyl, haloalkyl, alkenyl,~~
19 ~~cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl~~
20 ~~halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
21 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
22 ~~on the indazole ring to any extent: including, but not~~
23 ~~limited to, AMB, 5F-AMB;~~

24 (71) (Blank); ~~Methyl 2-(1H-indazole 3-carboxamido)-~~
25 ~~3,3-dimethylbutanoate with substitution on the nitrogen~~
26 ~~atom of the indazole ring by alkyl, haloalkyl, alkenyl,~~

1 ~~cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl~~
2 ~~halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
3 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
4 ~~on the indazole ring to any extent: including, but not~~
5 ~~limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;~~

6 (72) (Blank); ~~Methyl-2-(1H-indole-3-carboxamido)-3-~~
7 ~~methylbutanoate with substitution on the nitrogen atom of~~
8 ~~the indole ring by alkyl, haloalkyl, alkenyl,~~
9 ~~cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl~~
10 ~~halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
11 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
12 ~~on the indazole ring to any extent: including, but not~~
13 ~~limited to, MMB018, MMB2201, and AMB-CHIMICA;~~

14 (73) (Blank); ~~Methyl-2-(1H-indole-3-carboxamido)-3,3-~~
15 ~~dimethylbutanoate with substitution on the nitrogen atom~~
16 ~~of the indole ring by alkyl, haloalkyl, alkenyl,~~
17 ~~cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl~~
18 ~~halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
19 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
20 ~~on the indazole ring to any extent: including, but not~~
21 ~~limited to, MDMB-CHIMICA;~~

22 (74) (Blank); ~~N-(1-amino-1-oxo-3-phenylpropan-~~
23 ~~-2-yl)-1H-indazole-3-carboxamide with substitution on the~~
24 ~~nitrogen atom of the indazole ring by alkyl, haloalkyl,~~
25 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,~~
26 ~~alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or~~

1 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
2 ~~on the indazole ring to any extent: including, but not~~
3 ~~limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;~~

4 (75) (Blank); ~~N-(1-Amino-1-oxo-3-phenylpropan-~~
5 ~~2-yl)-1H-indole-3-carboxamide with substitution on the~~
6 ~~nitrogen atom of the indole ring by alkyl, haloalkyl,~~
7 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,~~
8 ~~alkyl-aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or~~
9 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~
10 ~~on the indazole ring to any extent: including, but not~~
11 ~~limited to, APP-PICA and 5-fluoro-APP-PICA;~~

12 (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
13 4-AcO-DMT;

14 (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
15 name 5-MeO-MIPT;

16 (78) 4-hydroxy Diethyltryptamine (4-HO-DET);

17 (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);

18 (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);

19 (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
20 (4-HO-MiPT);

21 (82) (Blank); ~~Fluorophenylpiperazine;~~

22 (83) Methoxetamine;

23 (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
24 ethcathinone).

25 (e) Unless specifically excepted or unless listed in
26 another schedule, any material, compound, mixture, or

1 preparation which contains any quantity of the following
2 substances having a depressant effect on the central nervous
3 system, including its salts, isomers, and salts of isomers
4 whenever the existence of such salts, isomers, and salts of
5 isomers is possible within the specific chemical designation:

6 (1) mecloqualone;

7 (2) methaqualone; and

8 (3) gamma hydroxybutyric acid.

9 (f) Unless specifically excepted or unless listed in
10 another schedule, any material, compound, mixture, or
11 preparation which contains any quantity of the following
12 substances having a stimulant effect on the central nervous
13 system, including its salts, isomers, and salts of isomers:

14 (1) Fenethylline;

15 (2) N-ethylamphetamine;

16 (3) Aminorex (some other names:

17 2-amino-5-phenyl-2-oxazoline; aminoxaphen;

18 4-5-dihydro-5-phenyl-2-oxazolamine) and its

19 salts, optical isomers, and salts of optical isomers;

20 (4) Methcathinone (some other names:

21 2-methylamino-1-phenylpropan-1-one;

22 Ephedrone; 2-(methylamino)-propiofenone;

23 alpha-(methylamino)propiofenone; N-methylcathinone;

24 methcathinone; Monomethylpropion; UR 1431) and its

25 salts, optical isomers, and salts of optical isomers;

26 (5) Cathinone (some trade or other names:

1 2-aminopropiophenone; alpha-aminopropiophenone;

2 2-amino-1-phenyl-propanone; norephedrone);

3 (6) N,N-dimethylamphetamine (also known as:

4 N,N-alpha-trimethyl-benzeneethanamine;

5 N,N-alpha-trimethylphenethylamine);

6 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-

7 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);

8 (8) 3,4-Methylenedioxypropylamphetamine (MDPV);

9 (9) Halogenated amphetamines and

10 methamphetamines - any compound derived from either

11 amphetamine or methamphetamine through the substitution

12 of a halogen on the phenyl ring, including, but not

13 limited to, 2-fluoroamphetamine, 3-

14 fluoroamphetamine and 4-fluoroamphetamine;

15 (10) Aminopropylbenzofuran (APB):

16 including 4-(2-Aminopropyl) benzofuran, 5-

17 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)

18 benzofuran, and 7-(2-Aminopropyl) benzofuran;

19 (11) Aminopropyl-dihydrobenzofuran (APDB):

20 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,

21 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,

22 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,

23 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;

24 (12) Methylaminopropylbenzofuran

25 (MAPB): including 4-(2-methylaminopropyl)

26 benzofuran, 5-(2-methylaminopropyl)benzofuran,

1 6-(2-methylaminopropyl)benzofuran
2 and 7-(2-methylaminopropyl)benzofuran; ~~+~~
3 (13) Methylaminopropyl-dihydrobenzofuran
4 (MAPDB): including 1-(2,3-dihydrobenzofuran-5-yl)-
5 N-methylpropan-2-amine.

6 (g) Temporary listing of substances subject to emergency
7 scheduling. Any material, compound, mixture, or preparation
8 that contains any quantity of the following substances:

9 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
10 (benzylfentanyl), its optical isomers, isomers, salts, and
11 salts of isomers;

12 (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
13 phenylpropanamide (thenylfentanyl), its optical isomers,
14 salts, and salts of isomers.

15 (h) Synthetic cathinones. Unless specifically excepted,
16 any chemical compound which is not approved by the United
17 States Food and Drug Administration or, if approved, is not
18 dispensed or possessed in accordance with State or federal
19 law, not including bupropion, structurally derived from
20 2-aminopropan-1-one by substitution at the 1-position with
21 either phenyl, naphthyl, or thiophene ring systems, whether or
22 not the compound is further modified in one or more of the
23 following ways:

24 (1) by substitution in the ring system to any extent
25 with alkyl, alkylendioxy, alkoxy, haloalkyl, hydroxyl, or
26 halide substituents, whether or not further substituted in

1 the ring system by one or more other univalent
2 substituents. Examples of this class include, but are not
3 limited to, 3,4-Methylenedioxcathinone (bk-MDA);

4 (2) by substitution at the 3-position with an acyclic
5 alkyl substituent. Examples of this class include, but are
6 not limited to, 2-methylamino-1-phenylbutan-1-one
7 (buphedrone); or

8 (3) by substitution at the 2-amino nitrogen atom with
9 alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
10 inclusion of the 2-amino nitrogen atom in a cyclic
11 structure. Examples of this class include, but are not
12 limited to, Dimethylcathinone, Ethcathinone, and
13 a-Pyrrolidinopropiophenone (a-PPP); or

14 Any other synthetic cathinone which is not approved by the
15 United States Food and Drug Administration or, if approved, is
16 not dispensed or possessed in accordance with State or federal
17 law.

18 (i) Synthetic cannabinoids or piperazines. Any synthetic
19 cannabinoid or piperazine which is not approved by the United
20 States Food and Drug Administration or, if approved, which is
21 not dispensed or possessed in accordance with State and
22 federal law.

23 (1) As used in this Section, "synthetic cannabinoid"
24 includes, but is not limited to, any compound, as
25 identified in a report from an accredited forensic
26 laboratory, that is structurally derived from any one or

1 more of the following compounds:

2 (A) Any compound structurally derived from
3 3-(1-naphthoyl)indole or
4 1H-indol-3-yl-(1-naphthyl)methane by substitution at
5 the nitrogen atom of the indole ring by alkyl,
6 haloalkyl, alkenyl, cycloalkylmethyl,
7 cycloalkylethyl, aryl halide, alkyl aryl halide,
8 1-(N-methyl-2-piperidinyl)methyl, or
9 2-(4-morpholinyl)ethyl whether or not further
10 substituted in the indole ring to any extent, whether
11 or not substituted in the naphthyl ring to any extent.
12 Examples of this structural class include, but are not
13 limited to, JWH-018, AM-2201, JWH-175, JWH-184, and
14 JWH-185;

15 (B) 3-(1-naphthoyl)pyrrole by substitution at the
16 nitrogen atom of the pyrrole ring by alkyl, haloalkyl,
17 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
18 halide, alkyl aryl halide,
19 1-(N-methyl-2-piperidinyl)methyl, or
20 2-(4-morpholinyl)ethyl, whether or not further
21 substituted in the pyrrole ring to any extent, whether
22 or not substituted in the naphthyl ring to any extent.
23 Examples of this structural class include, but are not
24 limited to, JWH-030, JWH-145, JWH-146, JWH-307, and
25 JWH-368;

26 (C) 1-(1-naphthylmethyl)indene by substitution at

1 the 3-position of the indene ring by alkyl, haloalkyl,
2 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
3 halide, alkyl aryl halide,
4 1-(N-methyl-2-piperidinyl)methyl, or
5 2-(4-morpholinyl)ethyl whether or not further
6 substituted in the indene ring to any extent, whether
7 or not substituted in the naphthyl ring to any extent.
8 Examples of this structural class include, but are not
9 limited to, JWH-176;

10 (D) 3-phenylacetylindole by substitution at the
11 nitrogen atom of the indole ring with alkyl,
12 haloalkyl, alkenyl, cycloalkylmethyl,
13 cycloalkylethyl, aryl halide, alkyl aryl halide,
14 1-(N-methyl-2-piperidinyl)methyl, or
15 2-(4-morpholinyl)ethyl, whether or not further
16 substituted in the indole ring to any extent, whether
17 or not substituted in the phenyl ring to any extent.
18 Examples of this structural class include, but are not
19 limited to, JWH-167, JWH-250, JWH-251, and RCS-8;

20 (E) 2-(3-hydroxycyclohexyl)phenol by substitution
21 at the 5-position of the phenolic ring by alkyl,
22 haloalkyl, alkenyl, cycloalkylmethyl,
23 cycloalkylethyl, aryl halide, alkyl aryl halide,
24 1-(N-methyl-2-piperidinyl)methyl, or
25 2-(4-morpholinyl)ethyl, whether or not substituted in
26 the cyclohexyl ring to any extent. Examples of this

1 structural class include, but are not limited to, CP
2 47, 497 and its C8 homologue (cannabicyclohexanol);

3 (F) 3-(benzoyl) indole with substitution at the
4 nitrogen atom of the indole ring by an alkyl,
5 haloalkyl, alkenyl, cycloalkylmethyl,
6 cycloalkylethyl, aryl halide, alkyl aryl halide,
7 1-(N-methyl-2-piperidinyl)methyl, or
8 2-(4-morpholinyl)ethyl group whether or not further
9 substituted in the indole ring to any extent and
10 whether or not substituted in the phenyl ring to any
11 extent. Examples of this structural class include, but
12 are not limited to, AM-630, AM-2233, AM-694,
13 Pravadoline (WIN 48,098), and RCS-4;

14 (G) 3-cyclopropoylindole with substitution at the
15 nitrogen atom of the indole ring by alkyl, haloalkyl,
16 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
17 halide, alkyl aryl halide,
18 1-(N-methyl-2-piperidinyl)methyl, or
19 2-(4-morpholinyl)ethyl, whether or not further
20 substituted on the indole ring to any extent, whether
21 or not substituted on the cyclopropyl ring to any
22 extent, including, but not limited to, XLR11, UR144,
23 FUB-144;

24 (H) 3-adamantoylindole with substitution at the
25 nitrogen atom of the indole ring by alkyl, haloalkyl,
26 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl

1 halide, alkyl aryl halide,
2 1-(N-methyl-2-piperidinyl)methyl, or
3 2-(4-morpholinyl)ethyl, whether or not further
4 substituted on the indole ring to any extent, whether
5 or not substituted on the adamantyl ring to any
6 extent, including, but not limited to, AB-001;

7 (I) N-(adamantyl)-indole-3-carboxamide with
8 substitution at the nitrogen atom of the indole ring
9 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
10 cycloalkylethyl, aryl halide, alkyl aryl halide,
11 1-(N-methyl-2-piperidinyl)methyl, or
12 2-(4-morpholinyl)ethyl, whether or not further
13 substituted on the indole ring to any extent, whether
14 or not substituted on the adamantyl ring to any
15 extent, including, but not limited to, APICA/2NE-1,
16 STS-135;

17 (J) N-(adamantyl)-indazole-3-carboxamide with
18 substitution at a nitrogen atom of the indazole ring
19 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
20 cycloalkylethyl, aryl halide, alkyl aryl halide,
21 1-(N-methyl-2-piperidinyl)methyl, or
22 2-(4-morpholinyl)ethyl, whether or not further
23 substituted on the indazole ring to any extent,
24 whether or not substituted on the adamantyl ring to
25 any extent, including, but not limited to, AKB48,
26 5F-AKB48;

1 substituted on the benzimidazole ring to any extent,
2 whether or not substituted on the naphthyl ring to any
3 extent, including, but not limited to, FUBIMINA;

4 (N) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-
5 indazole-3-carboxamide with substitution on the
6 nitrogen atom of the indazole ring by alkyl,
7 haloalkyl, alkenyl, cycloalkylmethyl,
8 cycloalkylethyl, aryl halide, alkyl aryl halide,
9 1-(N-methyl-2-piperidinyl)methyl, or
10 2-(4-morpholinyl)ethyl, whether or not further
11 substituted on the indazole ring to any extent,
12 including, but not limited to, AB-PINACA, AB-FUBINACA,
13 AB-CHMINACA;

14 (O) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-
15 1H-indazole-3-carboxamide with substitution on the
16 nitrogen atom of the indazole ring by alkyl,
17 haloalkyl, alkenyl, cycloalkylmethyl,
18 cycloalkylethyl, aryl halide, alkyl aryl halide,
19 1-(N-methyl-2-piperidinyl)methyl, or
20 2-(4-morpholinyl)ethyl, whether or not further
21 substituted on the indazole ring to any extent,
22 including, but not limited to, ADB-PINACA,
23 ADB-FUBINACA;

24 (P) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-
25 1H-indole-3-carboxamide with substitution on the
26 nitrogen atom of the indole ring by alkyl, haloalkyl,

1 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
2 halide, alkyl aryl halide,
3 1-(N-methyl-2-piperidinyl)methyl, or
4 2-(4-morpholinyl)ethyl, whether or not further
5 substituted on the indole ring to any extent,
6 including, but not limited to, ADBICA, 5F-ADBICA;

7 (Q) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-
8 indole-3-carboxamide with substitution on the nitrogen
9 atom of the indole ring by alkyl, haloalkyl, alkenyl,
10 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
11 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
12 2-(4-morpholinyl)ethyl, whether or not further
13 substituted on the indole ring to any extent,
14 including, but not limited to, ABICA, 5F-ABICA;

15 (R) Methyl 2-(1H-indazole-3-carboxamido)-
16 3-methylbutanoate with substitution on the nitrogen
17 atom of the indazole ring by alkyl, haloalkyl,
18 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
19 halide, alkyl aryl halide,
20 1-(N-methyl-2-piperidinyl)methyl, or
21 2-(4-morpholinyl)ethyl, whether or not further
22 substituted on the indazole ring to any extent,
23 including, but not limited to, AMB, 5F-AMB;

24 (S) Methyl 2-(1H-indazole-3-carboxamido)-
25 3,3-dimethylbutanoate with substitution on the
26 nitrogen atom of the indazole ring by alkyl,

1 haloalkyl, alkenyl, cycloalkylmethyl,
2 cycloalkylethyl, aryl halide, alkyl aryl halide,
3 1-(N-methyl-2-piperidinyl)methyl, or
4 2-(4-morpholinyl)ethyl, whether or not further
5 substituted on the indazole ring to any extent,
6 including, but not limited to, 5-fluoro-MDMB-PINACA,
7 MDMB-FUBINACA;

8 (T) Methyl 2-(1H-indole-3-carboxamido)-3-
9 methylbutanoate with substitution on the nitrogen atom
10 of the indole ring by alkyl, haloalkyl, alkenyl,
11 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
12 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
13 2-(4-morpholinyl)ethyl, whether or not further
14 substituted on the indole ring to any extent,
15 including, but not limited to, MMB018, MMB2201, and
16 AMB-CHMICA;

17 (U) Methyl 2-(1H-indole-3-carboxamido)-3,3-
18 dimethylbutanoate with substitution on the nitrogen
19 atom of the indole ring by alkyl, haloalkyl, alkenyl,
20 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
21 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
22 2-(4-morpholinyl)ethyl, whether or not further
23 substituted on the indazole indole ring to any extent,
24 including, but not limited to, MDMB-CHMICA;

25 (V) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
26 indazole-3-carboxamide with substitution on the

1 nitrogen atom of the indazole ring by alkyl,
2 haloalkyl, alkenyl, cycloalkylmethyl,
3 cycloalkylethyl, aryl halide, alkyl aryl halide,
4 1-(N-methyl-2-piperidinyl)methyl, or
5 2-(4-morpholinyl)ethyl, whether or not further
6 substituted on the indazole ring to any extent,
7 including, but not limited to, APP-CHMINACA,
8 5-fluoro-APP-PINACA;

9 (W) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-
10 1H-indole-3-carboxamide with substitution on the
11 nitrogen atom of the indole ring by alkyl, haloalkyl,
12 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
13 halide, alkyl aryl halide,
14 1-(N-methyl-2-piperidinyl)methyl, or
15 2-(4-morpholinyl)ethyl, whether or not further
16 substituted on the indole ring to any extent,
17 including, but not limited to, APP-PICA and
18 5-fluoro-APP-PICA;

19 (X) 1H-indazole-3-carboxylic acid 8-quinolinyl
20 ester with substitution at the nitrogen atom of the
21 indazole ring by alkyl, haloalkyl, alkenyl,
22 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
23 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
24 2-(4-morpholinyl)ethyl, whether or not further
25 substituted on the inazdole ring to any extent,
26 whether or not substituted on the quinoline ring to

1 any extent, including, but not limited to, SDB-005,
2 5-F-SDB-005;

3 (2) As used in this Section, "synthetic piperazine"
4 includes, but is not limited to, any of the following
5 compounds and their positional isomers:

6 (A) N-Benzylpiperazine (BZP);

7 (B) Trifluoromethylphenylpiperazine (TFMPP);

8 (C) Fluorophenylpiperazine;

9 (D) Chlorophenylpiperazine.

10 (j) Unless specifically excepted or listed in another
11 schedule, any chemical compound which is not approved by the
12 United States Food and Drug Administration or, if approved, is
13 not dispensed or possessed in accordance with State or federal
14 law, and is derived from the following structural classes and
15 their salts:

16 (1) Benzodiazepine class: A fused 1,4-diazepine and
17 benzene ring structure with a phenyl connected to the
18 1,4-diazepine ring, with any substitution(s) or
19 replacement(s) on the 1,4-diazepine or benzene ring, any
20 substitution(s) on the phenyl ring, or any combination
21 thereof. Examples of this class include but are not
22 limited to: Clonazolam, Flualprazolam; or

23 (2) Thienodiazepine class: A fused 1,4-diazepine and
24 thiophene ring structure with a phenyl connected to the
25 1,4-diazepine ring, with any substitution(s) or
26 replacement(s) on the 1,4-diazepine or thiophene ring, any

1 substitution(s) on the phenyl ring, or any combination
2 thereof. Examples of this class include but are not
3 limited to: Etizolam.

4 (k) Fentanyl-related substances.

5 (1) As used in this Section, "fentanyl-related
6 substance" means any compound, as identified in a report
7 from an accredited forensic laboratory, unless
8 specifically excepted or listed under another schedule,
9 that is not approved by the United States Food and Drug
10 Administration or, if approved, is not dispensed or
11 possessed in accordance with State or federal law and that
12 is structurally derived from fentanyl
13 (N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)-
14 propanamide) by one or more of the following
15 modifications:

16 (A) replacement of the phenyl portion of the
17 phenethyl group by any monocycle, whether or not
18 further substituted in or on the monocycle;

19 (B) substitution in or on the phenethyl group with
20 alkyl, alkenyl, alkoxy, hydroxyl, halo, haloalkyl,
21 amino, or nitro groups;

22 (C) substitution in or on the piperidine ring with
23 alkyl, alkenyl, alkoxy, ester, ether, hydroxyl, halo,
24 haloalkyl, amino, or nitro groups;

25 (D) replacement of the aniline ring with any
26 aromatic monocycle whether or not further substituted

1 in or on the aromatic monocycle; or
2 (E) replacement of the N-propionyl group by
3 another acyl group.

4 (2) "Fentanyl-related substance" includes, but is not
5 limited to, the following substances:

6 (A) Acetyl-alpha-methylfentanyl;

7 (B) Alpha-methylfentanyl (N-(1-alpha-methyl-beta-
8 phenyl)ethyl-4-piperidyl) propionanilide;
9 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)
10 piperidine;

11 (C) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-
12 thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);

13 (D) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-
14 phenethyl)-4-piperidinyl]-N-phenylpropanamide

15 (E) 3-Methylfentanyl (N-[3-methyl-1-(2-
16 phenylethyl)-4-piperidyl]-N-phenylpropanamide);

17 (F) 3-Methylthiofentanyl (N-[(3-methyl-1-
18 (2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);

19 (G) Para-fluorofentanyl (N-(4-fluorophenyl)-
20 N-[1-(2-phenethyl)-4-piperidinyl]propanamide);

21 (H) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-
22 4-piperidinyl]-propanamide);

23 (I) Beta-hydroxy-3-methylfentanyl (other name:
24 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-
25 4-piperidinyl]-N-phenylpropanamide);

26 (J) Furanyl fentanyl (FU-F);

- 1 (K) Butyryl fentanyl;
2 (L) Valeryl fentanyl;
3 (M) Acetyl fentanyl;
4 (N) Beta-hydroxy-thiofentanyl;
5 (O) Acrylfentanyl (acryloylfentanyl);
6 (P) Cyclopropyl fentanyl;
7 (Q) Crotonyl fentanyl;
8 (R) Methoxyacetyl fentanyl;
9 (S) Pentanoyl fentanyl;
10 (T) Cyclopentyl fentanyl;
11 (U) Isobutyryl fentanyl;
12 (V) Benzodioxolefentanyl;
13 (W) Tetrahydrofuran fentanyl.

14 (Source: P.A. 103-245, eff. 1-1-24.)

15 (720 ILCS 570/206) (from Ch. 56 1/2, par. 1206)

16 Sec. 206. (a) The controlled substances listed in this
17 Section are included in Schedule II.

18 (b) Unless specifically excepted or unless listed in
19 another schedule, any of the following substances whether
20 produced directly or indirectly by extraction from substances
21 of vegetable origin, or independently by means of chemical
22 synthesis, or by combination of extraction and chemical
23 synthesis:

24 (1) Opium and opiates, and any salt, compound,
25 derivative or preparation of opium or opiate, excluding

1 apomorphine, dextrorphan, levopropoxyphene, nalbuphine,
2 nalmefene, naloxone, and naltrexone, and their respective
3 salts, but including the following:

4 (i) Raw Opium;

5 (ii) Opium extracts;

6 (iii) Opium fluid extracts;

7 (iv) Powdered opium;

8 (v) Granulated opium;

9 (vi) Tincture of opium;

10 (vii) Codeine;

11 (viii) Ethylmorphine;

12 (ix) Etorphine Hydrochloride;

13 (x) Hydrocodone;

14 (xi) Hydromorphone;

15 (xii) Metopon;

16 (xiii) Morphine;

17 (xiii.5) 6-Monoacetylmorphine;

18 (xiv) Oxycodone;

19 (xv) Oxymorphone;

20 (xv.5) Tapentadol;

21 (xvi) Thebaine;

22 (xvii) Thebaine-derived butorphanol.

23 (xviii) Methorphan, except drug products
24 containing dextromethorphan that may be dispensed
25 pursuant to a prescription order of a practitioner and
26 are sold in compliance with the safety and labeling

1 standards as set forth by the United States Food and
2 Drug Administration, or drug products containing
3 dextromethorphan that are sold in solid, tablet,
4 liquid, capsule, powder, thin film, or gel form and
5 which are formulated, packaged, and sold in dosages
6 and concentrations for use as an over-the-counter drug
7 product. For the purposes of this Section,
8 "over-the-counter drug product" means a drug that is
9 available to consumers without a prescription and sold
10 in compliance with the safety and labeling standards
11 as set forth by the United States Food and Drug
12 Administration.

13 (2) Any salt, compound, isomer, derivative or
14 preparation thereof which is chemically equivalent or
15 identical with any of the substances referred to in
16 subparagraph (1), but not including the isoquinoline
17 alkaloids of opium;

18 (3) Opium poppy and poppy straw;

19 (4) Coca leaves and any salt, compound, isomer, salt
20 of an isomer, derivative, or preparation of coca leaves
21 including cocaine or ecgonine, and any salt, compound,
22 isomer, derivative, or preparation thereof which is
23 chemically equivalent or identical with any of these
24 substances, but not including decocainized coca leaves or
25 extractions of coca leaves which do not contain cocaine or
26 ecgonine (for the purpose of this paragraph, the term

1 "isomer" includes optical, ~~positional~~ and geometric
2 isomers);

3 (5) Concentrate of poppy straw (the crude extract of
4 poppy straw in either liquid, solid or powder form which
5 contains the phenanthrine alkaloids of the opium poppy).

6 (c) Unless specifically excepted or unless listed in
7 another schedule any of the following opiates, including their
8 isomers, esters, ethers, salts, and salts of isomers, whenever
9 the existence of these isomers, esters, ethers and salts is
10 possible within the specific chemical designation, dextrorphan
11 excepted:

12 (1) Alfentanil;

13 (1.1) Carfentanil;

14 (1.2) Thiafentanyl;

15 (2) Alphaprodine;

16 (3) Anileridine;

17 (4) Bezitramide;

18 (5) Bulk Dextropropoxyphene (non-dosage forms);

19 (6) Dihydrocodeine;

20 (7) Diphenoxylate;

21 (8) Fentanyl;

22 (9) Sufentanil;

23 (9.5) Remifentanil;

24 (10) Isomethadone;

25 (11) (Blank);

26 (12) Levorphanol (Levorphan);

- 1 (13) Metazocine;
- 2 (14) Methadone;
- 3 (15) Methadone-Intermediate,
4 4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
- 5 (16) Moramide-Intermediate,
6 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
7 acid;
- 8 (17) Pethidine (meperidine);
- 9 (18) Pethidine-Intermediate-A,
10 4-cyano-1-methyl-4-phenylpiperidine;
- 11 (19) Pethidine-Intermediate-B,
12 ethyl-4-phenylpiperidine-4-carboxylate;
- 13 (20) Pethidine-Intermediate-C,
14 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 15 (21) Phenazocine;
- 16 (22) Piminodine;
- 17 (23) Racemethorphan;
- 18 (24) (Blank);
- 19 (25) Levo-alpha-acetylmethadol (some other names:
20 levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).
- 21 (d) Unless specifically excepted or unless listed in
22 another schedule, any material, compound, mixture, or
23 preparation which contains any quantity of the following
24 substances having a stimulant effect on the central nervous
25 system:
- 26 (1) Amphetamine, its salts, optical isomers, and salts

1 of its optical isomers;

2 (2) Methamphetamine, its salts, isomers, and salts of
3 its isomers;

4 (3) Phenmetrazine and its salts;

5 (4) Methylphenidate;

6 (5) Lisdexamfetamine.

7 (e) Unless specifically excepted or unless listed in
8 another schedule, any material, compound, mixture, or
9 preparation which contains any quantity of the following
10 substances having a depressant effect on the central nervous
11 system, including its salts, isomers, and salts of isomers
12 whenever the existence of such salts, isomers, and salts of
13 isomers is possible within the specific chemical designation:

14 (1) Amobarbital;

15 (2) Secobarbital;

16 (3) Pentobarbital;

17 (4) Pentazocine;

18 (5) Phencyclidine;

19 (6) Gluthethimide;

20 (7) (Blank).

21 (f) Unless specifically excepted or unless listed in
22 another schedule, any material, compound, mixture, or
23 preparation which contains any quantity of the following
24 substances:

25 (1) Immediate precursor to amphetamine and
26 methamphetamine:

- 1 (i) Phenylacetone
2 Some trade or other names: phenyl-2-propanone;
3 P2P; benzyl methyl ketone; methyl benzyl ketone.
4 (2) Immediate precursors to phencyclidine:
5 (i) 1-phenylcyclohexylamine;
6 (ii) 1-piperidinocyclohexanecarbonitrile (PCC).
7 (3) Nabilone.
8 (Source: P.A. 100-368, eff. 1-1-18.)

9 (720 ILCS 570/208) (from Ch. 56 1/2, par. 1208)

10 Sec. 208. (a) The controlled substances listed in this
11 Section are included in Schedule III.

12 (b) Unless specifically excepted or unless listed in
13 another schedule, any material, compound, mixture, or
14 preparation which contains any quantity of the following
15 substances having a stimulant effect on the central nervous
16 system, including its salts, isomers (whether optical
17 position, or geometric), and salts of such isomers whenever
18 the existence of such salts, isomers, and salts of isomers is
19 possible within the specific chemical designation;

20 (1) Those compounds, mixtures, or preparations in
21 dosage unit form containing any stimulant substances
22 listed in Schedule II which compounds, mixtures, or
23 preparations were listed on August 25, 1971, as excepted
24 compounds under Title 21, Code of Federal Regulations,
25 Section 308.32, and any other drug of the quantitative

1 composition shown in that list for those drugs or which is
2 the same except that it contains a lesser quantity of
3 controlled substances;

- 4 (2) Benzphetamine;
- 5 (3) Chlorphentermine;
- 6 (4) Clortermine;
- 7 (5) Phendimetrazine.

8 (c) Unless specifically excepted or unless listed in
9 another schedule, any material, compound, mixture, or
10 preparation which contains any quantity of the following
11 substances having a potential for misuse associated with a
12 depressant effect on the central nervous system:

13 (1) Any compound, mixture, or preparation containing
14 amobarbital, secobarbital, pentobarbital or any salt
15 thereof and one or more other active medicinal ingredients
16 which are not listed in any schedule;

17 (2) Any suppository dosage form containing
18 amobarbital, secobarbital, pentobarbital or any salt of
19 any of these drugs and approved by the Federal Food and
20 Drug Administration for marketing only as a suppository;

21 (3) Any substance which contains any quantity of a
22 derivative of barbituric acid, or any salt thereof:

- 23 (3.1) Aprobarbital;
- 24 (3.2) Butobarbital (secbutobarbital);
- 25 (3.3) Butalbital;
- 26 (3.4) Butobarbital (butethal);

- 1 (4) Chlorhexadol;
- 2 (5) Methyprylon;
- 3 (6) Sulfondiethylmethane;
- 4 (7) Sulfonethylmethane;
- 5 (8) Sulfonmethane;
- 6 (9) Lysergic acid;
- 7 (10) Lysergic acid amide;
- 8 (10.1) Tiletamine or zolazepam or both, or any salt of
- 9 either of them.
- 10 Some trade or other names for a tiletamine-zolazepam
- 11 combination product: Telazol.
- 12 Some trade or other names for Tiletamine:
- 13 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
- 14 Some trade or other names for zolazepam:
- 15 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
- 16 [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.
- 17 (11) Any material, compound, mixture or preparation
- 18 containing not more than 12.5 milligrams of pentazocine or
- 19 any of its salts, per 325 milligrams of aspirin;
- 20 (12) Any material, compound, mixture or preparation
- 21 containing not more than 12.5 milligrams of pentazocine or
- 22 any of its salts, per 325 milligrams of acetaminophen;
- 23 (13) Any material, compound, mixture or preparation
- 24 containing not more than 50 milligrams of pentazocine or
- 25 any of its salts plus naloxone HCl USP 0.5 milligrams, per
- 26 dosage unit;

1 (14) Ketamine;

2 (15) Thiopental;~~;~~

3 (16) Xylazine.

4 (d) Nalorphine.

5 (d.5) Buprenorphine.

6 (e) Unless specifically excepted or unless listed in
7 another schedule, any material, compound, mixture, or
8 preparation containing limited quantities of any of the
9 following narcotic drugs, or their salts calculated as the
10 free anhydrous base or alkaloid, as set forth below:

11 (1) not more than 1.8 grams of codeine per 100
12 milliliters or not more than 90 milligrams per dosage
13 unit, with an equal or greater quantity of an isoquinoline
14 alkaloid of opium;

15 (2) not more than 1.8 grams of codeine per 100
16 milliliters or not more than 90 milligrams per dosage
17 unit, with one or more active non-narcotic ingredients in
18 recognized therapeutic amounts;

19 (3) (blank);

20 (4) (blank);

21 (5) not more than 1.8 grams of dihydrocodeine per 100
22 milliliters or not more than 90 milligrams per dosage
23 unit, with one or more active, non-narcotic ingredients in
24 recognized therapeutic amounts;

25 (6) not more than 300 milligrams of ethylmorphine per
26 100 milliliters or not more than 15 milligrams per dosage

1 unit, with one or more active, non-narcotic ingredients in
2 recognized therapeutic amounts;

3 (7) not more than 500 milligrams of opium per 100
4 milliliters or per 100 grams, or not more than 25
5 milligrams per dosage unit, with one or more active,
6 non-narcotic ingredients in recognized therapeutic
7 amounts;

8 (8) not more than 50 milligrams of morphine per 100
9 milliliters or per 100 grams with one or more active,
10 non-narcotic ingredients in recognized therapeutic
11 amounts.

12 (f) Anabolic steroids, except the following anabolic
13 steroids that are exempt:

- 14 (1) Androgyn L.A.;
- 15 (2) Andro-Estro 90-4;
- 16 (3) depANDROGYN;
- 17 (4) DEPO-T.E.;
- 18 (5) depTESTROGEN;
- 19 (6) Duomone;
- 20 (7) DURATESTRIN;
- 21 (8) DUO-SPAN II;
- 22 (9) Estratest;
- 23 (10) Estratest H.S.;
- 24 (11) PAN ESTRA TEST;
- 25 (12) Premarin with Methyltestosterone;
- 26 (13) TEST-ESTRO Cypionates;

- 1 (14) Testosterone Cyp 50 Estradiol Cyp 2;
2 (15) Testosterone Cypionate-Estradiol Cypionate
3 injection; and
4 (16) Testosterone Enanthate-Estradiol Valerate
5 injection.

6 (g) Hallucinogenic substances.

- 7 (1) Dronabinol (synthetic) in sesame oil and
8 encapsulated in a soft gelatin capsule in a U.S. Food and
9 Drug Administration approved product. Some other names for
10 dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
11 6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or
12 (-)-delta-9-(trans)-tetrahydrocannabinol.

13 (2) (Reserved).

14 (h) The Department may except by rule any compound,
15 mixture, or preparation containing any stimulant or depressant
16 substance listed in subsection (b) from the application of all
17 or any part of this Act if the compound, mixture, or
18 preparation contains one or more active medicinal ingredients
19 not having a stimulant or depressant effect on the central
20 nervous system, and if the admixtures are included therein in
21 combinations, quantity, proportion, or concentration that
22 vitiate the potential for misuse of the substances which have
23 a stimulant or depressant effect on the central nervous
24 system.

25 (Source: P.A. 103-881, eff. 1-1-25.)

1 (720 ILCS 570/309.1 new)

2 Sec. 309.1. Xylazine exemptions. Notwithstanding the
3 scheduling of xylazine as a Schedule III controlled substance,
4 xylazine shall not be considered a controlled substance when:

5 (1) used by licensed Illinois veterinarians dispensing
6 or prescribing for, or administering to, a nonhuman
7 species of a drug containing xylazine that has been
8 approved by the U.S. Food and Drug Administration;

9 (2) used by licensed Illinois veterinarians dispensing
10 or prescribing for, or administering to, a nonhuman
11 species that is permissible under the Federal Food, Drug,
12 and Cosmetic Act;

13 (3) manufactured, distributed, or used as an active
14 pharmaceutical ingredient for manufacturing an animal drug
15 approved under the Federal Food, Drug, and Cosmetic Act;

16 (4) used by a licensed certified euthanasia technician
17 employed by a certified euthanasia agency; or

18 (5) used by a wildlife biologist engaged in legal or
19 authorized fieldwork under the indirect supervision of a
20 veterinarian.

21 Section 99. Effective date. This Act takes effect January
22 1, 2027.